Clene enters third-year NIH subaward with NYU for up to $8M for ALS expanded access program

Clene Inc.

Third-year subaward under $45.1M NIH grant; up to $8M for period 9/1/2025–8/31/2026.
Funds support Expanded Access Program for CNM-Au8 treatment of amyotrophic lateral sclerosis (ALS).
Subaward with New York University as prime awardee; replaces prior subaward with Columbia University for first two years.
Either party may terminate with 30 days' notice; Company retains Background IP and no licenses granted to NYU or US Gov.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Clene Inc. entered into Year 3 Subaward with New York University (NYU) valued at up to $8.0 million (effective 2026-03-13).

Action: entry
Counterparty: New York University (NYU)
Value: up to $8.0 million
Effective: 2026-03-13

Exact text from the filing

On March 13, 2026, the Company entered into a subaward agreement for the third year of the NIH Grant with New York University (“NYU”), the prime awardee, for up to $8.0 million during the period from September 1, 2025 to August 31, 2026 (the “Year 3 Subaward”).

View on SEC.gov

312 material agreements filed in the last 30 days. Browse all material agreements →

Clene Inc. filing history →

Source: SEC EDGAR

accession 0001437749-26-008482

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.